The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
MK-1084 for KRAS G12C-mutated (mut) metastatic non–small-cell lung cancer (mNSCLC): Results from KANDLELIT-001.
 
Adrian Sacher
Research Funding - Amgen (Inst); AstraZeneca (Inst); BMS (Inst); Bridgebio (Inst); CRISPR Therapeutics (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Hotspot Therapeutics (Inst); Iovance Biotherapeutics (Inst); Lilly Loxo (Inst); Merck (Inst); Pfizer (Inst); Spectrum Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - Amgen; Genentech/Roche; Merck
(OPTIONAL) Uncompensated Relationships - Amgen; Genentech/Roche; Merck
 
Mehmet Sendur
Honoraria - Amgen; Astellas Pharma; Bayer; Bristol-Myers Squibb; Janssen; MSD; Novartis; Pfizer; Roche; Takeda
Speakers' Bureau - Abdi Ibrahim; Abdi Ibrahim; Amgen; Astellas Pharma; Bristol-Myers Squibb; Janssen; Novartis; Pfizer; Roche; Takeda
 
Anastasios Stathis
Consulting or Advisory Role - AstraZeneca (Inst); Bayer (Inst); Debiopharm Group (Inst); Incyte; Incyte (Inst); Janssen Oncology (Inst); Loxo/Lilly (Inst); Novartis (Inst); Roche (Inst)
Research Funding - Abbvie (Inst); ADC Therapeutics (Inst); Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); BMS GmbH & Co. KG (Inst); BMS GmbH & Co. KG (Inst); Cellestia Biotech (Inst); Debiopharm Group (Inst); Incyte (Inst); Lilly (Inst); Loxo (Inst); MEI Pharma (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Philogen (Inst); Prelude Therapeutics (Inst); Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Incyte (Inst)
 
Maya Gottfried
Consulting or Advisory Role - Boehringer Ingelheim (Inst); Pfizer (Inst); Roche (Inst)
Research Funding - MSD (Inst)
Travel, Accommodations, Expenses - Boehringer Ingelheim; Pfizer; Roche
 
Shun Lu
Leadership - Innovent BIOLOGICS, INC; Shanghai Fosun; Simcere Zaiming
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; GenomiCare; Hutchison MediPharma; InventisBio Co. Ltd; Menarini; Pfizer; Roche; Simcere; Yuhan; Zai Lab
Speakers' Bureau - AstraZeneca; Hansoh Pharma; Hengrui Therapeutics; Roche
Research Funding - AstraZeneca (Inst); BeiGene (Inst); BMS (Inst); Hansoh (Inst); Hengrui Therapeutics (Inst); Hutchison MediPharma (Inst); Lilly Suzhou Pharmaceutical Co. (Inst); Roche (Inst)
 
Rosalyn Juergens
Honoraria - Amgen; AstraZeneca; Bayer; Bristol-Myers Squibb; Janssen Oncology; Jazz Pharmaceuticals; Merck Sharp & Dohme; Mirati Therapeutics; Novartis Canada Pharmaceuticals Inc; Pfizer; Roche Canada; Sanofi; Takeda
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Bristol-Myers Squibb; EMD Serono; Fusion Pharmaceuticals; Janssen Oncology; Jazz Pharmaceuticals; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Roche Canada; Sanofi/Regeneron; Takeda
Research Funding - Alkermes (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bold Therapeutics (Inst); Bristol-Myers Squibb (Inst); Fusion Pharmaceuticals (Inst); Janssen (Inst); Macrogenics (Inst); Merck Sharp & Dohme (Inst); mirai (Inst); Novartis (Inst); Pfizer (Inst)
 
Laiyu Liu
Research Funding - MSD (Inst)
 
Carlos Rojas
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Knight Therapeutics/Biotoscana; Merck Sharp & Dohme; Pfizer; Roche
Research Funding - AstraZeneca; Bristol-Myers Squibb/Celgene; Knight Therapeutics/Biotoscana; Merck; Pfizer; Roche
Expert Testimony - AstraZeneca; Bristol-Myers Squibb; Roche
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Jair Bar
Consulting or Advisory Role - Abbvie; AstraZeneca; Bayer; BeiGene; Bristol-Myers Squibb; Janssen Oncology; Medison; Merck Serono; MSD; Novartis; Pfizer; Roche; Takeda
Research Funding - Abbvie (Inst); AstraZeneca/MedImmune (Inst); Immunai (Inst); MSD (Inst); Novartis (Inst); Oncohost (Inst); Pfizer (Inst); Roche (Inst); Takeda (Inst)
 
Victor Moreno
Employment - START
Consulting or Advisory Role - Abbvie; Affimed Therapeutics; AstraZeneca; Basilea; Bayer; BMS; Ellipses Pharma; Janssen Oncology; Merck; Roche
Speakers' Bureau - Bayer; Pierre Fabre
Research Funding - Abbvie (Inst); ACEA Biosciences (Inst); Adaptimmune (Inst); ADC Therapeutics (Inst); Amgen (Inst); Ascendis Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); Bicycle Therapeutics (Inst); Bioinvent (Inst); Biomea Fusion (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); C4 Therapeutics (Inst); Celgene (Inst); Constellation Pharmaceuticals (Inst); Crescendo Bioscience (Inst); Cullinan Oncology (Inst); E-therapeutics (Inst); Eisai (Inst); F-Star Biotechnology (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Grey Wolf Therapeutics (Inst); hemavant (Inst); HiFiBiO Therapeutics (Inst); Janssen (Inst); Kinnate Biopharma (Inst); Menarini (Inst); Merck (Inst); MonTa Biosciences (Inst); Nanobiotix (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); PsiOxus Therapeutics (Inst); Puma Biotechnology (Inst); Regeneron (Inst); Revolution Medicines (Inst); RigonTEC (Inst); Roche (Inst); Sanofi (Inst); Sierra Oncology (Inst); Synthon (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Tesaro (Inst); Transgene (Inst)
Expert Testimony - Medscape/Bayer; Nanobiotix
Travel, Accommodations, Expenses - Sanofi/Regeneron
Other Relationship - BMS
 
Yun Fan
No Relationships to Disclose
 
Mustafa Erman
Honoraria - Abdi Ibrahim; Astellas Pharma; Bristol-Myers Squibb; Deva; Eczacibasi; Janssen; Novartis; Pfizer; Roche
Consulting or Advisory Role - Astellas Pharma; Deva; Eczacibasi; Janssen; Merck; Nobelpharma; Pfizer; Roche
Speakers' Bureau - Abdi Ibrahim; Astellas Pharma; Bristol-Myers Squibb; Deva; Eczacibasi; Janssen; Novartis; Pfizer; Roche
Research Funding - AstraZeneca (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Incyte (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Regeneron (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; Eczacibasi; Gen; Merck; MSD; Novartis; Roche
 
Nir Peled
Leadership - Israeli Lung Cancer Foundation
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; MSD; Novartis; Pfizer; Roche; Takeda
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Imagene AI; Lilly; MSD; Novartis; Pfizer; Roche
Research Funding - AstraZeneca (Inst); Merck Serono (Inst); MSD Oncology (Inst); Novartis (Inst); Roche/Genentech (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - AstraZeneca; MSD Oncology; Pfizer; Roche/Genentech
 
Enriqueta Felip
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol Myers Squibb; Daiichi Sankyo Europe GmbH; Gilead Sciences; GlaxoSmithKline; ITeos Therapeutics; Johnson & Johnson/Janssen; Merck Sharp & Dohme; Novartis; Pfizer; Pierre Fabre; Regeneron; Roche; Turning Point Therapeutics
Speakers' Bureau - Amgen; AstraZeneca; Bristol Myers Squibb; Daiichi Sankyo; Genentech; Gilead Sciences; Johnson & Johnson/Janssen; Lilly; Medical Trends; Medscape; Merck Serono; Merck Sharp & Dohme; Novartis; Peervoice; Pfizer; Regeneron; Roche
Travel, Accommodations, Expenses - AstraZeneca; Janssen; Roche
Other Relationship - GRIFOLS
(OPTIONAL) Uncompensated Relationships - "ETOP IBCSG Partners" Member of the Scientific Committee; “Medical writing assistance for this abstract was provided by Nimisha H. Bhoola, PhD, of Nucleus Global, an Inizio Company, and funded by F. Hoffmann-La Roche Ltd.”; Member of the Scientific Advisory Committee -Hospital Universitari Parc Taulí-; SEOM (Sociedad Española de Oncología Médica), President from 2021-2023
 
Mark Ayers
Employment - Merck Sharp & Dohme
Stock and Other Ownership Interests - Merck
 
Thomas Jemielita
Employment - Merck
Stock and Other Ownership Interests - Merck
 
L. Rhoda Molife
Employment - MSD
Stock and Other Ownership Interests - Merck
 
Yewon Choi
Employment - Merck Sharp & Dohme
Stock and Other Ownership Interests - C4 Therapeutics; Oscotec; Relay Therapeutics
 
Rafal Dziadziuszko
Honoraria - AstraZeneca; Bristol-Myers Squibb; GlaxoSmithKline; MSD Oology; Pfizer; Roche/Genentech
Consulting or Advisory Role - GlaxoSmithKline
Travel, Accommodations, Expenses - AstraZeneca; GlaxoSmithKline; Pfizer